Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.63M P/E - EPS this Y 34.10% Ern Qtrly Grth -
Income -9.29M Forward P/E -1.70 EPS next Y 46.90% 50D Avg Chg 1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.32 EPS next 5Y - 52W High Chg -73.00%
Recommedations 1.70 Quick Ratio 8.08 Shares Outstanding 3.23M 52W Low Chg 42.00%
Insider Own 0.83% ROA -37.09% Shares Float 3.20M Beta 1.20
Inst Own 0.78% ROE -59.63% Shares Shorted/Prior 6.08K/20.19K Price 1.97
Gross Margin - Profit Margin - Avg. Volume 12,629 Target Price 16.67
Oper. Margin - Earnings Date May 9 Volume 9,328 Change 0.00%
About Artelo Biosciences, Inc.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc. News
04/23/24 Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
04/22/24 Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
03/25/24 Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
03/12/24 Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
02/15/24 Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
01/23/24 Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
01/08/24 Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
12/05/23 Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
11/30/23 Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
11/13/23 Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
11/09/23 Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
11/02/23 Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
10/04/23 Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
09/13/23 Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
09/07/23 Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
09/06/23 Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
09/05/23 Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
08/10/23 Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
07/19/23 Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
07/10/23 Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
ARTL Chatroom

User Image Gunther77 Posted - 04/30/24

$ARTL one would think reclassification should be good for $ARTL . Will we be able to tell?

User Image Stock_Titan Posted - 04/23/24

$ARTL Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy https://www.stocktitan.net/news/ARTL/artelo-biosciences-announces-publication-of-peer-reviewed-article-qmloiq0yi95x.html

User Image Ramano413 Posted - 04/22/24

$ARTL

User Image Stock_Titan Posted - 04/22/24

$ARTL Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time https://www.stocktitan.net/news/ARTL/artelo-biosciences-ceo-to-appear-on-benzinga-all-access-on-april-j8d7mfy4l661.html

User Image ProfProfit Posted - 04/18/24

$ARTL $GLYC Fuck

User Image Gunther77 Posted - 04/18/24

$ARTL if any of their patents or research was worth a 💩, they would have been scooped up by now. All we have to look forward to is more dilution followed by another RS.

User Image Gunther77 Posted - 04/18/24

$ARTL 8⅔ cents pre split now, and 4.2m cap. 🤷‍♂️

User Image Gunther77 Posted - 04/17/24

$ARTL 11k volume, how sad 😔. That's a whole $15,000. Pathetic

User Image drpower2000 Posted - 04/09/24

@aricray @Multipliers you keep posting about investors so you are telling me that any big investor has a 100% return rate on every investment? If you think that, I have a $1M pet rock I want to sell you. Plain and simple big investor get investments WRONG all the time. The key is to get bigger win than loses. Obviously they expect a return, but it doesn’t mean they will get it. Also they may be satisfied with a 300% return. Where that won’t even get most people on here back to there cost basis. So this is FAR from guaranteed. At this point I give it a 20% odds and that being generous based on most $ARTL $CRBP $GWPH $RVVTF $SKYE tech trial results.

User Image Nexxie Posted - 04/09/24

$ARTL HC PTs are garbage. Please show examples of stocks when they hit. I hope JnJ buys us

User Image Mystock9 Posted - 04/02/24

$ARTL HC had PT on this but no volume. May be good future growth.

User Image Ramano413 Posted - 1 month ago

$ARTL

User Image Nexxie Posted - 03/26/24

$ARTL I smell something coming soon

User Image Stock_Titan Posted - 03/25/24

$ARTL Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update https://www.stocktitan.net/news/ARTL/artelo-biosciences-reports-fiscal-2023-year-end-financial-results-6hnwtpze7069.html

User Image TimingTimingTiming Posted - 03/21/24

$ARTL All this needs is for a few experienced traders to move in here and it’s all over This would go parabolic

User Image manuelfaf Posted - 03/21/24

$ARTL clarification, is the last (bottom) file.

User Image LongBallBarn Posted - 03/21/24

$VTVT $UPC $ARTL $HOLO lol easy adds

User Image Gunther77 Posted - 03/20/24

$ARTL you would think an ultra low float stock with a paltry less than $5m cap would do something with good PR like patent approvals. 🤷‍♂️🤔

User Image manuelfaf Posted - 03/20/24

$ARTL anyone can explain a little the last doc from the patent in https://register.epo.org/application?number=EP18887462&lng=en&tab=doclist?

User Image onurc Posted - 03/20/24

$ARTL I was wondering what caused the spike. I am not sure, though, how big of a catalyst this patent is.

User Image PatentGrants Posted - 03/20/24

$ARTL Artelo Biosciences has received a decision to grant European patent number EP3723752 titled "NEW SOLID FORMS OF CANNABIDIOL AND USES THEREOF (FOR VARIOUS MEDICAL TREATMENTS)". https://register.epo.org/application?number=EP18887462

User Image Gunther77 Posted - 03/14/24

$ARTL meh, this stock just goes down on PR. Hey, Johnson & Johnson, take us out of our misery and buy them for $4 a share

User Image Stock_Titan Posted - 03/12/24

$ARTL Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge https://www.stocktitan.net/news/ARTL/artelo-biosciences-selected-as-a-finalist-in-johnson-johnson-s-6eabzueu009g.html

User Image Ramano413 Posted - 03/11/24

$ARTL

User Image LongBallBarn Posted - 03/08/24

$MNMD $LSDI $PSIL $ARTL Anyone with half a brain knows this is the next huge thing just like 3D printers were 5 years ago, AI the past 2 years etc...

User Image ProfProfit Posted - 03/07/24

$ARTL what a pile of shit

User Image Ramano413 Posted - 03/04/24

$ARTL

User Image ProfProfit Posted - 1 month ago

$ARTL 😒 cant believe back under 1.50 again

User Image Nexxie Posted - 02/29/24

$ARTL patents granted wen

User Image LongBallBarn Posted - 02/27/24

$SYRA $MNMD $AVGR $ARTL

Analyst Ratings
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Nov 14, 23
Ladenburg Thalmann Buy Apr 3, 23
HC Wainwright & Co. Buy Feb 3, 23
HC Wainwright & Co. Buy Aug 12, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gorgas Gregory D. Pres, CEO, CFO, Trea.. Pres, CEO, CFO, Treas & Secr Aug 12 Buy 4.00 1,200 4,800 2,400 08/12/22
Gorgas Gregory D. Pres, CEO, CFO, Trea.. Pres, CEO, CFO, Treas & Secr Aug 11 Buy 4.03 1,200 4,836 1,200 08/11/22